#frontier pharma

Report Description

The report states that the pipeline of Parkinson’s disease currently has 302 products across a number of developmental stages. However a stark contrast between the mechanisms of action of the current products of the market and the ones in pipeline is evident. Currently employed PD therapeutic methods target neuromodulatory receptors; however, the products in the pipeline feature a number of neuroprotective therapies that target dysfunctional disease processes.

The diversity in the variety of products is owing to the presence of 90 first-in-class therapies, accounting for nearly 37% of the overall therapies in the pipeline. The PD market landscape is one that favors first-in-class therapies over non-first-in-class ones. Despite of the high attrition rate of first-in-class therapies, the therapies that make it to the market have the potential of improving the PD treatment landscape and transforming the market place.

Complete Report with TOC @ http://www.mrrse.com/frontier-pharma-parkinsons-disease

Scope

Parkinson\'s disease (PD) is a progressive neurological health condition that features a clichéd interplay between a number of pathological processes and features neurodegeneration as one of its key effects. In the U.S. alone, nearly 50,000 - 60,000 new cases of PD are diagnosed every year. Other than these, there are already nearly one million patients of PD in the US and nearly four to six million PD patients in the entire world. It is ranked as the 14th leading cause of death in the US. The exact cause behind PD is not clear. Still, scientists are working towards a cure for the condition and many therapeutic methods are in their developmental phases. As a result of the enormous research efforts being undertaken on a global level and technical advancements in the field of medicine, the knowledge of the processes involved in neurodegeneration has been broadened. Also, the knowledge base regarding the neuroanatomy of basal ganglia, a factor that is important for studying the causes of PD, is highly developed.

Table of Contents

1 Table of Contents 2 1.1 List of Figures 2 Executive Summary 5 2.1 Highly Innovative and Diverse Pipeline 5 2.2 Alignment of Innovation to Disease Processes and Genetics 5 2.3 Deals Landscape Present Substantial Investment Opportunities 5 3 The Case for Innovation 6 3.1 Growing Opportunities for Biologic Products 7 3.2 Diversification of Molecular Targets 7 3.3 Innovative First-in-Class Product Developments Remain Attractive 7 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8 3.5 Sustained Innovation 8 3.6 GBI Research Report Guidance 9 4 Clinical and Commercial Landscape 10 5 Assessment of Pipeline Product Innovation 37 6 Pain Patent Analysis 7 First-in-Class Target and Pipeline Program Evaluation 8 Deals and Strategic Consolidations 9 Appendix

Request a Sample Copy of the Report @ http://www.mrrse.com/sample/131

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact Corporate Office State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States

Report Description

The gap between the market and pipeline is huge. According to the latest data, the market at present contains 70 products, and majority of these products are generic formulations of chemotherapies, which are not frequently used for treating patients at the advanced-stage. Nexavar (sorafenib) is the top therapeutic product in the global liver cancer market. This therapeutic product is only targeted therapy which is in frequent use for advanced stage liver cancer patients. Nevertheless, the pipeline evaluation showed that targeted therapies towards the principal oncogenic signaling pathways are under bigger spotlight in the pipeline than in the market.

The success of these targeted therapies in the liver cancer market and oncology market as a whole shows that the innovation and diversity in the pipeline is a promising sign. It also shows that currently the products in pipeline possess the potential to transcend and enhance the relatively open liver cancer market.

Complete Report with TOC @ http://www.mrrse.com/frontier-pharma-liver-cancer

Scope

Particularly in the liver cancer pipeline, there are 238 products currently in active development, and around 47% of these are first-in-class drugs. The percentage of pipeline devoted to novel products is substantially higher as compared to both the oncology and industry average. This is a promising sign for innovative therapeutics aiming for the liver cancer market.

Table of Contents

1 Table of Contents 1.1 List of Figures 2 Executive Summary 2.1 Unmet Needs and Limited Market Drive an Innovative Pipeline 2.2 Targeted Therapies Segment to Expand over the Coming Decade 2.3 Active Deals Landscape Reflects the Dynamic Pipeline 3 The Case for Innovation 3.1 Growing Opportunities for Biologic Products 3.2 Diversification of Molecular Targets 3.3 Innovative First-in-class Product Developments Remain Attractive 4 Clinical and Commercial Landscape 4.1 Disease Overview 4.2 Symptoms 4.3 Epidemiology and Etiology 4.4 Pathophysiology 5 Assessment of Pipeline Product Innovation 6 Pain Patent Analysis 7 First-in-Class Target and Pipeline Program Evaluation 8 Deals and Strategic Consolidations 9 Appendix

Request a Sample Copy of the Report @ http://www.mrrse.com/sample/110

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact Corporate Office State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States

Report Description

The gap between the market and pipeline is huge. According to the latest data, the market at present contains 70 products, and majority of these products are generic formulations of chemotherapies, which are not frequently used for treating patients at the advanced-stage. Nexavar (sorafenib) is the top therapeutic product in the global liver cancer market. This therapeutic product is only targeted therapy which is in frequent use for advanced stage liver cancer patients. Nevertheless, the pipeline evaluation showed that targeted therapies towards the principal oncogenic signaling pathways are under bigger spotlight in the pipeline than in the market.

The success of these targeted therapies in the liver cancer market and oncology market as a whole shows that the innovation and diversity in the pipeline is a promising sign. It also shows that currently the products in pipeline possess the potential to transcend and enhance the relatively open liver cancer market.

Complete Report with TOC @ http://www.mrrse.com/frontier-pharma-liver-cancer

Scope

Particularly in the liver cancer pipeline, there are 238 products currently in active development, and around 47% of these are first-in-class drugs. The percentage of pipeline devoted to novel products is substantially higher as compared to both the oncology and industry average. This is a promising sign for innovative therapeutics aiming for the liver cancer market.

Table of Contents

1 Table of Contents 1.1 List of Figures 2 Executive Summary 2.1 Unmet Needs and Limited Market Drive an Innovative Pipeline 2.2 Targeted Therapies Segment to Expand over the Coming Decade 2.3 Active Deals Landscape Reflects the Dynamic Pipeline 3 The Case for Innovation 3.1 Growing Opportunities for Biologic Products 3.2 Diversification of Molecular Targets 3.3 Innovative First-in-class Product Developments Remain Attractive 4 Clinical and Commercial Landscape 4.1 Disease Overview 4.2 Symptoms 4.3 Epidemiology and Etiology 4.4 Pathophysiology 5 Assessment of Pipeline Product Innovation 6 Pain Patent Analysis 7 First-in-Class Target and Pipeline Program Evaluation 8 Deals and Strategic Consolidations 9 Appendix

Request a Sample Copy of the Report @ http://www.mrrse.com/sample/110

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact Corporate Office State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States

Report Description

The comprehensive analysis of the research report specifies that the granted patents for drugs have provided with a significant quantity of first-in-class product techniques, some of which have not been distinguished as yet in the pain pipelines. The allocation of these first-in-class products throughout the molecular target super-families and other families emphasize that they primarily align with the even distribution observed across the pain pipeline. Moreover, it will include the enzymes inhibitors and G-protein-coupled receptors that consist the two crucial categories. Nevertheless, a collection of novel molecular targets within the two categories has been specified, which is not present in any pipeline or marketed products across the market. A significant level of innovation has also been recognized in other molecular target classifications.

The research report provides an analysis of the licensing of products along with the co-development active deals for pain treatment. It also presents specifics on the increasing investment opportunities for drug manufacturing companies. In the past eight years, pain therapy deals have been majorly active, approximating 112 co-development deals and 261 licensing deals. The investments in this area have been enormous; however, the first-in-class products deals have been relatively less.

Complete Report with TOC @ http://www.mrrse.com/frontier-pharma-pain

Scope

The active pipeline of global pain treatment market holds around 796 products at different development stages showcasing a high variety of molecular targets. The research report has provided 122 first-in-class projects that are in active development stage, which constitute about 13.6% of the pipeline. Among this, 65 first-in-class molecule targets denote a high level of innovation.

Table of Contents

1 Table of Contents 1.1 List of Figures 2 Executive Summary 3 The Case for Innovation 4 Clinical and Commercial Landscape 5 Assessment of Pipeline Product Innovation 6 Pain Patent Analysis 7 First-in-Class Target and Pipeline Program Evaluation 8 Deals and Strategic Consolidations 9 Appendix

Request a Sample Copy of the Report @ http://www.mrrse.com/sample/108

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact Corporate Office State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States

Research Beam added a report “Frontier Pharma Pain-Identifying and Commercializing First-in-Class Innovation”.

Description

Large and Innovative Pipeline

The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation.

Enquiry @ http://www.researchbeam.com/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report

This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action. Moderate-to-severe pain continues to be dominated by opioids that are increasingly being reformulated to offer abuse-resistance, while mild pain is effectively treated with Non-Steroidal Anti-Inflammatory Drugs (NSAID). However, significant unmet needs remain, as chronic pain and some neuropathic pain subtypes do not respond well to existing therapies, which are not adequate to treat associated hypersensitization and do not align to the underlying molecular pathophysiological profile.

Despite being mostly distributed in the early stages of development, first-in-class innovation is particularly concentrated on novel molecular targets that are aligned to the central sensitization associated with neuropathic pain, which is arguably the most debilitating and difficult-to-treat type of chronic pain. This gives them the potential to transform the future market by expanding the range of drug classes.

Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents

Pain is a complex and multifaceted disorder with a complex interplay between different pathological processes, and different pain subtypes exhibit distinct underlying etiologies and pathophysiologies. While technological advances and extensive research efforts have furthered the understanding of these complex underpinnings, gaps remain. However, these insights have translated into the expanding pool of novel therapeutic targets, as reflected by the highly innovative pipeline. GBI Research’s proprietary analysis shows that early-stage, first-in-class programs exhibit a higher level of diversity with respect to novel therapeutic targets. The significant diversity in terms of targets is a reflection of the complex underpinnings of distinct pain subtypes. Although the pipeline continues to feature established therapies, the range of mechanisms of action employed by novel compounds is extremely diverse, with the vast majority residing in the Preclinical stage. This innovation and diversity is maintained throughout the pipeline from early- to late-stage development, although the degree of innovation diminishes from Phase II. Additionally, although NSAIDs and opioids remain the cornerstone of pain treatment, GBI Research analysis indicates a shift towards pain subtypes that are more difficult to treat. Encouragingly, these first-in-class compounds often target molecules which are strongly implicated in pain and its associated signaling pathways. Although there are significant differentiations in the scientific rationale and clinical prospects across these first-in-class products, the majority demonstrate significant Preclinical evidence and alignment to molecular pathophysiological changes.

In addition, GBI Research’s comprehensive and complementary analysis of granted patents highlighted a significant number of first-in-class product technologies, many of which have not been identified in the pain product pipelines or even in pipelines across the industry. The distribution of these products across the molecular target super families and families highlighted that they predominantly align with the proportional distribution observed across the pain pipeline, with G-protein-coupled receptors and enzymes inhibitors constituting the two major categories. However, an array of novel molecular targets within those groups has been identified, which do not present in any pipeline or marketed products across the industry. A significant degree of innovation has also been identified in other molecular target categories.

Active Deals Landscape with Numerous Investment Opportunities

The pain deals landscape has been highly active over the past eight years, with 261 licensing deals and 112 co-development deals. However, despite high levels of investment activity, deals for first-in-class products have been relatively rare.

Overall, more than 50% of deals involving first-in-class targets were settled in the early stages of development, which is a striking contrast with non-first-in-class products, which are more frequently entered into deals in the later stages of development. This reflects companies’ willingness to invest despite the high-risk profile of first-in-class products.

With 107 first-in-class products available for strategic consolidations, a wide variety of investment opportunities are available for licensing deals or co-development deals in pain. This will be encouraged by the growing unmet need for chronic pain therapies, and an increased understanding of the distinct underlying pathophysiologies of distinct pain sub-types, allowed by technological advances. Among these, some first-in-class products have demonstrated promising Preclinical evidence and have significant potential to become game-changing products, representing high-reward investments.

Scope The report covers and includes: • A brief introduction to pain, including the different subtypes of pain, pathophysiology, and overview of pharmacotherapy and treatment algorithms • The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline • A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target • Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets • Assessment of the licensing and co-development deal landscape for pain therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products

Reasons to Buy • The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to: • Understand the focal shifts in molecular targets in the pain therapeutics pipeline • Understand the distribution of pipeline programs by phase of development, molecule type and molecular target • Access a scientific and clinical analysis of first-in-class developmental programs for pain, benchmarked against non-first-in-class targets • Access a list of the first-in-class therapies potentially open to deal-making opportunities

Table of Contents

1 Table of Contents 1.1 List of Figures

2 Executive Summary 2.1 Large and Innovative Pipeline 2.2 Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents 2.3 Active Deals landscape with Numerous Investment Oppertunities

3 The Case for Innovation 3.1 Growing Opportunities for Biologic Products 3.2 Diversification of Molecular Targets 3.3 Innovative First-in-Class Product Development Remains Attractive 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 3.5 Sustained Innovation 3.6 GBI Research Report Guidance

4 Clinical and Commercial Landscape 4.1 Disease Overview 4.1.1 Chronic and Neuropathic Pain 4.1.2 Disease Pathophysiology 4.1.3 Diagnosis 4.1.4 Treatment Option

4.1.5 Treatment Algorithm 4.2 Overview of Marketed Products for Pain 4.2.1 Analgesic Product Categories 4.2.2 Molecular Type Analysis 4.2.3 Molecular Target Analysis 4.2.4 Current Unmet Needs

5 Assessment of Pipeline Product Innovation 5.1 Pain Pipeline by Molecule Type, Phase and Therapeutic Targets 5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family 5.3 First-in-Class Pipeline Programs 5.4 First-in-Class Targets by Pain Subtype

Source: http://www.researchbeam.com/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation-market

About Us: We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell our authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities. In order to survive the fierce competition and locate different avenues, one must be privy to high end and quality market information. So, we try and provide you with latest market information by getting high market research reports from our clients.

In the United States, almost 1.5 million people are reported to be affected by Parkinson’s disease (PD), wherein 60,000 patients continue to be diagnosed with the condition every year, costing the U.S. economy US$14 billion on an annual basis in the direct and indirect expenses.

 Browse the full Global Parkinson’s Disease Market Report : http://www.mrrse.com/frontier-pharma-parkinsons-disease

 At present, 302 products are being actively developed in the therapeutic pipeline of Parkinson’s disease over a number of stages.

However, the mechanisms of action applied on the existing products compared to the ones in the pipeline shows severe differences. The existing symptomatic treatments employed for PD target neuromodulatory receptors; whereas, the current product pipeline features a widespread array of neuroprotective therapies focusing on dysfunctional disease procedures.

The availability of ninety first-in-class products that holds 37% of the overall therapies in pipeline is one of the major reason behind the diversity in the MoA for both, existing products and pipeline products.

Since, the global PD industry is driven by first-in-class products compared to the non-first-in-class ones; the development of this market is widely impacted by this factor. Although the first-in-class products and therapies have indicated high abrasion rate in past, they have the potential to modify the global PD treatment market for good.

As the global market for Parkinson’s disease is rising at a rapid pace, let’s take a look at the future prospects the market is going to deal with:

· The overall revenue generated from sales in the PD markets of the U.S., Germany, France, Italy, the U.K., Spain, and Japan is expected to register a slight decline from around US$2.7 billion in 2010 to an estimate of US$2.6 billion by 2020.

· The dominant dopamine agonists, ropinirole and pramipexole, are expected to trigger the sales significantly. The increasing usage of Agilect, the MAO-B inhibitor, and the resurgence of UCB’s Leganto/Neupro in the U.S. market with an even wider employment in the European market are also projected to drive the market growth.

· In spite of the increased uptake of some key therapies currently functional in the market and the announcement to launch 3 new agents (GlaxoSmithKline’s IPX-066, Newron Pharmaceuticals’ safinamide, and Kyowa Hakko Kirin’s istradefylline) by 2020, the sales of current agents and their impact on the market of emerging therapies is likely to be suppressed by generic competition.

 Send An Enquiry: http://www.mrrse.com/enquiry/131

 Table of Contents:

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 5

2.1 Highly Innovative and Diverse Pipeline 5

2.2 Alignment of Innovation to Disease Processes and Genetics 5

2.3 Deals Landscape Present Substantial Investment Opportunities 5

3 The Case for Innovation 6

3.1 Growing Opportunities for Biologic Products 7

3.2 Diversification of Molecular Targets 7

3.3 Innovative First-in-Class Product Developments Remain Attractive 7

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8

3.5 Sustained Innovation 8

3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10

4.1 Epidemiology 10

4.2 Disease Etiology 11

4.2.1 Exposure to Environmental Toxins 11

4.2.2 Genetic Causes of Familial Parkinson’s Disease 11

4.2.3 Susceptibility Genes for Parkinson’s Disease 13

4.3 Disease Pathophysiology 13

4.3.1 Basal Ganglia Anatomy and Physiology 13

4.3.2 Processes Underlying Neurodegeneration in Parkinson’s Disease 16

4.4 Disease Symptoms 20

4.5 Co-morbidities and Complications 20

4.6 Diagnosis 21

4.6.1 Classification 21

4.7 Prognosis and Disease Staging 23

4.8 Treatment Options 24

4.8.1 Pharmacological Treatment 24

4.8.2 Non-pharmacological Treatments 28

4.9 Marketed Product Overview 28

4.10 Overview of Marketed Products for Parkinson’s Disease 29

4.11 Efficacy and Safety of Marketed Products 31

4.12 Treatment Algorithm 33

4.13 Current Unmet Needs 35

5 Assessment of Pipeline Product Innovation 37

5.1 Parkinson’s Disease Pipeline by Molecule Type, Phase and Therapeutic Targets 37

5.2 Comparative Distribution of Programs between the Parkinson’s Disease Market and Pipeline by Therapeutic Target Family 41

6 Signaling Network, Parkinson’s Disease Genetics and Innovation Alignment 46

6.1 The Complexity of Signaling Network in Central Nervous System 46

6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 47

6.3 First-in-Class Target Matrix Assessment 51

7 First-in-Class Target and Pipeline Program Evaluation 54

7.1 Overview of Pipeline Programs Targeting ?-synuclein 54

7.2 Overview of Pipeline Programs Targeting LRRK2 57

7.3 Overview of Pipeline Programs Targeting Glial Cell-Derived Neurotrophic Factor 60

7.4 Overview of Pipeline Programs Targeting Progranulin 63

7.5 Overview of Pipeline Programs Targeting Cerebral Dopamine Neurotrophic Factor 66

7.6 Overview of Pipeline Programs Targeting Mesencephalic Astrocyte-Derived Neurotrophic Factor 68

7.7 Overview of Pipeline Programs Targeting Tyrosine Receptor Kinase B 70

7.8 Overview of Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 73

7.9 Overview of Pipeline Programs Targeting Metabotropic Glutamate Receptor 8 75

7.10 Overview of Pipeline Programs Targeting C-jun-N-Terminal Kinases 76

7.11 Overview of Pipeline Programs Targeting DJ-1 79

7.12 Overview of Pipeline Programs Targeting Reactive Oxygen Species 80

7.13 Overview of Pipeline Programs Targeting Heat Shock Transcription Factor 1 82

7.14 Overview of Pipeline Programs Targeting Heat Shock Protein 90 84

7.15 Overview of Pipeline Programs Targeting Growth Hormone Secretagogue Receptor 86

7.16 Overview of Pipeline Programs Targeting Protein Phosphatase 2A 88

7.17 Overview of Pipeline Programs Targeting Cytochrome P450 2D6 90

7.18 Conclusion 91

8 Deals and Strategic Consolidations 93

8.1 Industry-wide First-in-Class Deals 93

8.2 Parkinson’s Disease Deals Landscape 95

8.3 Licensing Deals 95

8.3.1 Molecule Type 97

8.3.2 Mechanism of Action 97

8.4 Co-development Deals 100

8.4.1 Mechanism of Action 101

8.5 First-in-Class Programs Not Involved in Licensing or Co-Development Deals 103

9 Appendix 106

9.1 Abbreviations 106

9.2 References 108

9.3 Contact Us 121

9.4 Disclaimer 121

 Latest Report:

Parabens Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 – 2020

http://www.mrrse.com/parabens-market

Description:

Para-hydroxybenzoic acid is commonly abbreviated using the term parabens. Parabens belong to the family of alkyl esters of para-hydroxybenzoic acid. Parabens mainly differ in the para position in the benzene ring due to various chemical substitutions.

There are various types of parabens or para-hydroxybenzoic acid available. However, methylparaben, ethylparaben, propylparaben, butylparaben, and benzylparaben are the widely marketed parabens.

 About Us:

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports.

Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice.

Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

 Contact

State Tower

90, State Street

Suite 700

Albany, NY - 12207

United States

Telephone: +1-518-618-1030

Email: [email protected]